Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study

Irit Ben‐Aharon(Technion – Israel Institute of Technology), David P. Kelsen(Memorial Sloan Kettering Cancer Center)

JMIR Public Health and Surveillance

November 7, 2023

Cited by 9

Related Papers

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

|Journal of Clinical Oncology|2005|1.1k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1k

Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face

|Cancer|1999|388

Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity?

|The American Journal of Surgical Pathology|2008|175

Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data

|European Journal of Cancer|2013|169